Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Pathol Lab Med. 2012 Dec;136(12):1482-91. doi: 10.5858/arpa.2012-0508-RA.

Lung cancer genotype-based therapy and predictive biomarkers: present and future.

Author information

  • 1Department of Pathology & Genomic Medicine, The Methodist Hospital, Houston, Texas, USA. pcagle@tmhs.org

Abstract

CONTEXT:

The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease.

OBJECTIVE:

To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist.

DATA SOURCES:

Data were obtained from review of the pertinent peer-reviewed literature.

CONCLUSIONS:

First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.

PMID:
23194040
DOI:
10.5858/arpa.2012-0508-RA
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Allen Press, Inc.
    Loading ...
    Support Center